Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
DAIICHI SANKYO COMPANY LIMITED	3-5-1 NIHONBASHI HONCHO CHUO-KU TOKYO 103-8426

International Classification(s)

• C07K:PEPTIDES

• [Classification Symbol]

• [Patents Count]

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Aoki, Takahiro	Tokyo, JP	167	2114
Kitagawa, Yutaka	Tokyo, JP	20	84
Kondo, Fumikatsu	Tokyo, JP	2	3
Kouko, Takashi	Tokyo, JP	2	3
Kurahashi, Kei	Tokyo, JP	4	3
Matuura, Shinji	Tokyo, JP	5	6
Nakamura, Tatsuya	Tokyo, JP	206	1881
Noguchi, Shigeru	Tokyo, JP	47	748
Sakanishi, Kohei	Tokyo, JP	6	7
Sato, Hitoshi	Tokyo, JP	212	4018
Takeda, Tadahiro	Tokyo, JP	7	13
Ueda, Tsuyoshi	Tokyo, JP	24	88
Yamaguchi, Tatsuya	Tokyo, JP	160	3658
Yamane, Yohei	Tokyo, JP	7	33

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
3.5 Year Payment	$1600.00	$800.00	$400.00	Oct 2, 2027
7.5 Year Payment	$3600.00	$1800.00	$900.00	Oct 2, 2031
11.5 Year Payment	$7400.00	$3700.00	$1850.00	Oct 2, 2035

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 3.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

DATE PUBLISHED	PUBLICATION/PATENT NO.	PUBLICATION TYPE
April 02, 2024	US,11945882,B2   US11945882B2	GRANTED PATENT AS SECOND PUBLICATION
December 10, 2020	US,20200385422,A1   US20200385422A1	FIRST PUBLISHED PATENT APPLICATION

Full Text

US Patent Application No: 11945882

Method for producing antibody-drug conjugate

---

 

Legal Events